Literature DB >> 34246562

Predictive factors of effective tibial nerve release in tarsal tunnel syndrome.

Maurice Bouysset1, Delphine Denarié2, Jean-Yves Coillard3, Daniel Boublil4, Matthieu Lalevée5, Thierry Tavernier6, Olivier Fantino7, Tiphaine Lefebvre8, Joel Damiano9, Cyrille B Confavreux10, Jacques G Tebib11, Fabienne Coury12.   

Abstract

BACKGROUND: Factors that may affect surgical decompression results in tarsal tunnel syndrome are not known.
METHODS: A retrospective single-center study included patients who had undergone surgical tibial nerve release. The effectiveness of decompression was evaluated according to whether the patient would or would not be willing to undergo another surgical procedure in similar preoperative circumstances.
RESULTS: The patients stated for 43 feet (51%) that they would agree to a further procedure in similar circumstances. Six feet with space-occupying lesions on imaging had improved results, but neurolysis failed in 9 feet with bone-nerve contact. Neurolysis was significantly less effective when marked hindfoot valgus (p = 0.034), varus (p = 0.014), or fasciitis (p = 0.019) were present.
CONCLUSIONS: If imaging reveals a compressive space-occupying lesion, surgery has a good prognosis. In feet with static hindfoot disorders or plantar fasciitis, conservative treatment must be optimized. Bone-nerve contact should systematically be sought.
Copyright © 2021 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Static hindfoot disorders; Tarsal tunnel syndrome

Mesh:

Year:  2021        PMID: 34246562     DOI: 10.1016/j.fas.2021.06.009

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.840


  1 in total

1.  Clinical Results Following Conservative Management of Tarsal Tunnel Syndrome Compared With Surgical Treatment: A Systematic Review.

Authors:  Neeraj Vij; Heather N Kaley; Christopher L Robinson; Peter P Issa; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Orthop Rev (Pavia)       Date:  2022-09-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.